Login / Signup

Short-Term Outcomes following "Switching" to Monthly Ranibizumab in Neovascular Age-Related Macular Degeneration Showing Insufficient Response to Bimonthly Aflibercept.

Jong Suk LeeHyun Goo KangChristopher Seungkyu LeeSe Joon Woo
Published in: Journal of ophthalmology (2021)
Switching to monthly ranibizumab in nAMD showing an insufficient response to bimonthly aflibercept led to immediate anatomical improvement. It can be considered in countries where the healthcare insurance system limits the minimum injection interval of aflibercept.
Keyphrases
  • age related macular degeneration
  • healthcare
  • health insurance
  • social media
  • endothelial cells